Frontlight ResearchEarly access
Gastric and oesophageal cancer trials in Spain
64 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- Where
- Barcelona, Burgos, Elche, L'Hospitalet de Llobregat, Madrid, Málaga, Ourense, Oviedo, Pamplona, Santander, Seville, Valencia
- Age
- 18 years and over
- People
- 510 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06644781 · EU 2023-509630-19-00 - Phase 1Not yet taking people in SpainA phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid
- Age
- 18 years and over
- People
- 64 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2024-518348-19-00 - No phaseTaking peopleThe EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
- Where
- Aranda de Duero, Barcelona, Burgos, Girona, Granollers, Majadahonda, Mérida, Ourense, Oviedo, Palma de Mallorca, Pamplona, Porto Cristo, Terrassa, Zaragoza
- Age
- 18 years and over
- People
- 1,200
- Run by
- EDUARDO ALBENIZ
See details and how to joinNCT05551416 - Phase 3Taking peopleA Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
- Where
- Badalona, Barcelona, Madrid, Ourense, Santander, Sevilla, Valencia
- Age
- 18 years and over
- People
- 840 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06764875 · EU 2024-512583-57-00 - Phase 3Taking peopleSonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Where
- Barcelona, Madrid, Pamplona, Santander, Santiago de Compostela, Valencia
- Age
- 18 years and over
- People
- 2,130 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07431281 · EU 2024-519787-40-00 - Phase 1Taking peopleStudy to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- Where
- Badalona, Barcelona, Madrid, Málaga, Pamplona, Zaragoza
- Age
- 18 years and over
- People
- 325 worldwide
- Run by
- AbbVie
See details and how to joinNCT06084481 · EU 2023-506227-29-00 - Phase 3Taking peopleA Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- Where
- Barcelona, Pamplona, Valencia, Zaragoza
- Age
- 18 years and over
- People
- 351 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT07043400 · EU 2025-522862-58-00 - Phase 2/3Taking peopleSymbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
- Where
- Barcelona, Madrid, Ourense
- Age
- 18 years and over
- People
- 840 worldwide
- Run by
- Pfizer
See details and how to joinNCT07392892 · EU 2025-524717-86-00 - Phase 1/2Taking peopleA Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Where
- Barcelona, Logroño, Madrid, Pozuelo de Alarcón, Valencia
- Age
- 18 years and over
- People
- 1,438 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07070232 · EU 2024-517261-16-00 - Phase 2Taking peopleAZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
- Where
- Barcelona, Madrid
- Age
- 18 years and over
- People
- 226 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06219941 · EU 2023-508275-37-00 - Phase 2Taking peopleStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Where
- Barcelona, Córdoba, Madrid, Málaga, Sevilla
- Age
- 18 years to 130 years
- People
- 454 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00 - Phase 1/2Taking peopleStudy of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Where
- Barcelona, Madrid, Pamplona, Seville, Valencia, Zaragoza
- Age
- 18 years and over
- People
- 534 worldwide
- Run by
- Revolution Medicines, Inc.
See details and how to joinNCT06128551 - Phase 1Active, not recruitingA Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Denikitug (GS-1811), an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination With an Anti–PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors
- Where
- Barcelona, Madrid, Pamplona, Pozuelo de Alarcón
- Age
- 18 years and over
- People
- 93 worldwide
- Run by
- Gilead Sciences Inc.
See details and how to joinNCT05007782 · EU 2022-501684-40-00 - Phase 1Taking peopleEvaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Where
- Barcelona, Madrid, Piqueras, Seville
- Age
- 18 years and over
- People
- 540 worldwide
- Run by
- SystImmune Inc.
See details and how to joinNCT05983432 - No phaseTaking peopleORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Where
- A Coruña, Barcelona, Girona, Las Palmas de Gran Canaria, Madrid, Málaga, Sabadell, Santiago de Compostela, Valencia
- Age
- 18 years and over
- People
- 2,285 worldwide
- Run by
- Guardant Health, Inc.
See details and how to joinNCT05059444 - Phase 1Taking peopleA Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
- Where
- Barcelona, L'Hospitalet de Llobregat, Murcia, Zaragoza
- Age
- 18 years and over
- People
- 398 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT05365581 · EU 2023-504514-29-00 - Phase 2Taking peopleTiming of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma
- Where
- Valencia
- Age
- 18 years and over
- People
- 290 worldwide
- Run by
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
See details and how to joinNCT07000253 - Phase 3Taking peopleTrial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab in First-line Metastatic HER2-positive Gastric or GEJ Cancer
- Where
- Badalona, Barcelona, Córdoba, Elche, L'Hospitalet de Llobregat, Madrid, Málaga, Murcia, Oviedo, Pamplona, Sevilla, Valencia
- Age
- 18 years and over
- People
- 228 worldwide
- Run by
- Daiichi Sankyo Inc.
See details and how to join2024-513122-27-00 - Phase 1/2Taking peopleA Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Where
- Badalona, Barcelona, Madrid, Málaga, Pamplona
- Age
- 18 years and over
- People
- 1,109 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT04895709 - Phase 1/2Taking peopleA Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Where
- Barcelona, Madrid, Valencia
- Age
- 18 years and over
- People
- 366 worldwide
- Run by
- Marengo Therapeutics, Inc.
See details and how to joinNCT05592626 · EU 2023-505334-10-01 - Phase 3Taking peopleStudy of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- Where
- Badalona, Barcelona, Córdoba, Elche, L'Hospitalet de Llobregat, Madrid, Málaga, Murcia, Oviedo, Pamplona, Seville, Valencia
- Age
- 18 years and over
- People
- 726 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06731478 - Phase 1Taking peopleA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid
- Age
- 18 years and over
- People
- 714 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00 - Phase 1Taking peopleA Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- Where
- L'Hospitalet de Llobregat, Madrid
- Age
- 18 years and over
- People
- 914 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT06131840 · EU 2023-505858-18-00 - Phase 1Taking peopleA Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Where
- Barcelona, Elche, Jerez de la Frontera, Madrid, Málaga, Santander
- Age
- 18 years and over
- People
- 1,006 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT04389632 · EU 2023-508469-34-00 - Phase 1/2Taking peopleBeamion BCGC-1: A study to find a suitable dose of zongertinib used alone and in combination with other treatments to test whether it helps people with different types of HER2+ cancer that has spread
- Where
- A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Sevilla, Valencia
- Age
- 18 years and over
- People
- 181 worldwide
- Run by
- Boehringer Ingelheim International GmbH
See details and how to join2023-509566-38-00